Total no. of patients, n (%) |
30 |
19 (63) |
11 (37) |
|
Female, n (%) |
16 (53) |
10 (55) |
6 (53) |
0.65 |
Oligoarticular, n (%) |
10 (33) |
6 (32) |
4 (36) |
|
Oligoarticular extended, n (%) |
2 (7) |
2 (11) |
1 (9) |
|
Polyarticular RF negative, n (%) |
13 (43) |
8 (42) |
4 (36) |
0.74 |
Enthesitis-related arthritis, n (%) |
4 (13) |
3 (16) |
1 (9) |
|
PsA, n (%) |
1 (3) |
0 (0) |
1 (9) |
|
Age at diagnosis, median (range), years |
5.5 (1.1–14.9) |
4.3 (1.1–14.9) |
6.9 (1.1–14.1) |
0.29 |
Age at examination, median (range), years |
9.8 (2.8–16.9) |
8.5 (2.8–15.7) |
10.5 (4.8–16.9) |
0.46 |
Disease duration, median (range), years |
2.4 (0.1–12.3) |
2.3 (0.1–12.3) |
2.6 (0.1–8.7) |
0.91 |
Global disease activity, median (mean, range), mm (n = 25) |
7 (12, 0–53) |
10 (12, 0–40) |
3 (12, 0–53) |
0.99 |
HLA-B27 positive/tested, n (%) (n = 27) |
1 (4) |
1/17 (6) |
0/10 (0) |
0.39 |
ANA positive, n (%) |
20 (67) |
13 (68) |
7 (64) |
1.0 |
Uveitis, n (%) |
4 (13) |
3 (16) |
1 (9) |
0.51 |
Median CHAQ score, (mean, range) (n = 23) |
0.0 (0.2, 0.0–1.0) |
0.0 (0.22, 0.0–1.0) |
0.0 (0.18, 0.0–0.75) |
0.77 |
Treatment with systemic disease-modifying drugs, % |
60 |
45 |
68 |
0.21 |